Resonant Capital Advisors LLC Acquires 1,512 Shares of Boston Scientific Corporation $BSX

Resonant Capital Advisors LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 31.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,343 shares of the medical equipment provider’s stock after buying an additional 1,512 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Boston Scientific were worth $681,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in BSX. 1248 Management LLC purchased a new position in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the 1st quarter valued at $27,000. Sound Income Strategies LLC increased its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Princeton Global Asset Management LLC purchased a new stake in Boston Scientific during the second quarter valued at about $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific during the second quarter worth about $37,000. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on BSX. Needham & Company LLC reissued a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Friday. Raymond James Financial raised their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday. Finally, Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Stock Down 1.3%

Shares of NYSE BSX opened at $101.08 on Monday. The business has a 50-day moving average of $101.14 and a 200-day moving average of $102.12. The firm has a market capitalization of $149.78 billion, a price-to-earnings ratio of 54.06, a PEG ratio of 2.04 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the company posted $0.63 earnings per share. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 170,214 shares of company stock valued at $17,548,337. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.